Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer

Eskiler, Gamze Güney2024-01-122024-01-122018-09Eskiler, G. G. vd. (2018). ''Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer''. Annals of Oncology, 29(Supplement 6).0923-7534https://www.sciencedirect.com/science/article/pii/S0923753419323026https://hdl.handle.net/11452/38977Bu çalışma, 14-15 Eylül, 2018 tarihlerinde Paris[Fransa]’da düzenlenen Conference on Molecular Analysis for Personalised Therapy (MAP) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessOncologyAssociation BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancerArticle00045824820006329Supplement 6https://doi.org/10.1093/annonc/mdy314.008Oncology1569-8041